Literature DB >> 20076935

[Tumors of the upper gastro-intestinal tract].

A Sendler1.   

Abstract

The appropriate extent of lymph node dissection in tumors of the upper gastro-intestinal tract continues to be debated. The basic tenet of surgical oncology that cancerous lymph nodes are indicators not governors of survival is under question and derives from the different theories of metastasis. Is the metastatic flow linear (indicators) or does it occur in parallel to tumorigenesis (governor)? If the latter theory is true there would be only a limited indication for lymphadenectomy (LA).Extended LA leads to an ameliorated staging of the N category. Following LA locoregional tumor control is significantly improved for esophageal and gastric cancer. In case of gastric cancer it is evident that there is a group of patients in which extended LA lead to improved long-term survival. This gain in prognosis affects patients in which lymph node metastasis is not or only slightly advanced. In locally advanced tumors there is no prognostic benefit. Patients who might benefit from the extended procedure cannot be assessed during preoperative staging. Therefore, the indications for the procedure should be liberally carried out by experienced hands and in experienced centers. According to randomized studies there is no indication for extended radical LA in pancreatic cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20076935     DOI: 10.1007/s00104-009-1813-x

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  42 in total

1.  Nodal dissection for patients with gastric cancer: a randomised controlled trial.

Authors:  Chew-Wun Wu; Chao A Hsiung; Su-Shun Lo; Mao-Chin Hsieh; Jen-Hao Chen; Anna Fen-Yau Li; Wing-Yiu Lui; Jacqueline Whang-Peng
Journal:  Lancet Oncol       Date:  2006-04       Impact factor: 41.316

2.  Quality of life and patterns of recurrence following transhiatal esophagectomy for cancer: results of a prospective follow-up in 50 patients.

Authors:  P A Barbier; P J Luder; G Schüpfer; C D Becker; H E Wagner
Journal:  World J Surg       Date:  1988-04       Impact factor: 3.352

3.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

Review 4.  Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer.

Authors:  Henk H Hartgrink; Cornelis J H van de Velde
Journal:  J Surg Oncol       Date:  2005-06-01       Impact factor: 3.454

5.  Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma.

Authors:  T Lerut; P Nafteux; J Moons; W Coosemans; G Decker; P De Leyn; D Van Raemdonck; N Ectors
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

6.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

7.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

8.  Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus.

Authors:  Jessica M Leers; Steven R DeMeester; Nadia Chan; Shahin Ayazi; Arzu Oezcelik; Emmanuele Abate; Farzaneh Banki; John C Lipham; Jeffrey A Hagen; Tom R DeMeester
Journal:  J Thorac Cardiovasc Surg       Date:  2009-07-14       Impact factor: 5.209

9.  Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma.

Authors:  P Edwards; G R J C Blackshaw; W G Lewis; J D Barry; M C Allison; D R B Jones
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

10.  Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer.

Authors:  M Degiuli; M Sasako; A Ponti; F Calvo
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.